Back to today’s briefing

Story perspectives

UK-US Deal: Tariff-Free Medicines, Higher U.S. Prices

4/3/2026

24 5 Full Breakdown

Summary

Story summary

On April 2, 2026, the United Kingdom and the United States announced an agreement granting tariff-free access for UK-made medicines.
The agreement commits zero tariffs for at least three years.
In exchange, prices for new U.S. medicines will be higher.
The National Health Service (NHS) will increase spending on new medicines by 25%.
The cost-effectiveness threshold of the National Institute for Health and Care Excellence (NICE) will be adjusted.

History

Historical Context

In 1998, the UK's National Health Service (NHS) faced budget constraints of approximately £60 billion, prompting healthcare funding reforms. This led to ongoing discussions about cost-effectiveness in medicine pricing. The recent agreement between the UK and US for tariff-free access to UK-made medicines may influence future international healthcare agreements, reflecting a significant shift in global pharmaceutical pricing strategies.

1 of 2

Story summary

On April 2, 2026, the United Kingdom and the United States announced an agreement granting tariff-free access for UK-made medicines.
The agreement commits zero tariffs for at least three years.
In exchange, prices for new U.S. medicines will be higher.
The National Health Service (NHS) will increase spending on new medicines by 25%.
The cost-effectiveness threshold of the National Institute for Health and Care Excellence (NICE) will be adjusted.

1 / 2